JOHNSON SABRINA MARTUCCI 4

What Happened Sabrina Martucci Johnson, Chief Executive Officer and Director of Dare Bioscience (DARE), received a grant of 172,000 derivative securities (stock-option award) on 2026-01-30. The Form 4 reports the acquisition amount as 172,000 shares at $0.00 (a derivative award), so there was no cash exchanged at grant. This is a compensation award rather than an open-market purchase or sale.

Key Details

• Transaction type: Award/Grant (derivative) reported on Form 4 for 2026-01-30, filed 2026-02-02.
• Amount: 172,000 options; price reported as $0.00 (reporting convention for awards).
• Vesting: Vests and becomes exercisable in 48 equal monthly installments beginning one month after the grant date, subject to continuous service (footnote F1).
• Shares owned after transaction: Not specified in the details provided in this summary.
• Timeliness: Filing date (Feb 2, 2026) is within the typical Form 4 reporting window for a Jan 30 transaction (filed timely).

Context This was a standard equity compensation grant to the CEO and not an exercise or sale. Such awards are common for executive compensation and do not alone signal a buy or sell decision by the insider. The options will vest gradually over four years (monthly), meaning any potential economic interest will accrue over time and subject to continued service.